Brief: Emergent BioSolutions Secures $17M Contract Update For TEMBEXA To Strengthen U.S. Smallpox Antiviral Supply Chain
15/09/2025 13:51
Sept 15 (Reuters) - Emergent BioSolutions Inc EBS.N: EMERGENT BIOSOLUTIONS SECURES $17 MILLION CONTRACT MODIFICATION FOR ORAL SUSPENSION TEMBEXA® (BRINCIDOFOVIR), A SMALLPOX ANTIVIRAL, AND STRENGTHENS OVERALL U.S. SUPPLY CHAIN Source text: ID:nGNX3vW015 Further company coverage: EBS.N ((Reuters.Briefs@thomsonreuters.com;))